A randomized placebo controlled trial of AZD8871 a novel dual acting bronchodilator in asthmatics.

E. Jimenez Lozano (Barcelona, Spain)

Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Session: Bronchodilators and bronchoprotectors
Session type: Poster Discussion
Number: 1811
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
E. Jimenez Lozano (Barcelona, Spain). A randomized placebo controlled trial of AZD8871 a novel dual acting bronchodilator in asthmatics.. 1811

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
A randomized placebo controlled trial of AZD8999 (LAS190792) a novel dual acting bronchodilator in asthmatics
Source: International Congress 2017 – Novel studies on bronchodilators and cough
Year: 2017



A randomized placebo and active controlled trial of AZD8871 a novel dual acting bronchodilator in COPD patients
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017

Short-term effect of a single dose of inhaled procaterol on exercise performance in COPD: a randomized, double blind, placebo-controlled, crossover trial
Source: Annual Congress 2008 - Physiological response to exercise performance
Year: 2008


Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial.
Source: International Congress 2018 – New developments in the treatment of asthma
Year: 2018


A randomized, double blind, cross-over study to investigate the pharmacodynamic equivalence of salbutamol administered via a new HFA134 inhaler versus Evohaler in mild stable asthmatics
Source: Eur Respir J 2006; 28: Suppl. 50, 210s
Year: 2006

A double-blind double dummy randomised placebo-controlled cross-over design clinical trial of formoterol delivered by two different dry powder devices in prevention of bronchoconstriction induced by methacholine in mild to moderate persistent asthma in adult patients
Source: Annual Congress 2009 - Airway hyperresponsiveness: mechanism and assessment
Year: 2009

A randomised controlled trial of zafirlukast in acute asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 254s
Year: 2005

A randomised controlled trial of the effect of a connected inhaler system on medication adherence in uncontrolled asthmatic patients
Source: Eur Respir J, 57 (6) 2003103; 10.1183/13993003.03103-2020
Year: 2021



A multi-centre, randomised, cross-over study to investigate therapy adherence with and preference for inhaled maintenance therapy via separate Diskus versus a combination product in one Diskus
Source: Eur Respir J 2002; 20: Suppl. 38, 448s
Year: 2002

Budesonide versus prednisone in acute wheezing: randomized double-blinded controlled placebo study
Source: Annual Congress 2008 - Treatment and outcome of childhood asthma: new perspectives
Year: 2008


Effect of salmetrol-fluticason combination and tiotropium on clinical and physiological improvement of bronchial anthracofibrosis, a double blind randomized, cross over, placebo controlled, clinical trial.
Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology
Year: 2017


Cardioselective beta-blockers are not only safe in patients with COPD, but may also improve the responsibility of FEV1 to beta-agonist: A meta-analysis of randomized controlled double-blinded trials
Source: Annual Congress 2012 - Pharmacological and non-pharmacological management of COPD
Year: 2012

Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011

Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial
Source: ERJ Open Res, 7 (3) 00255-2021; 10.1183/23120541.00255-2021
Year: 2021



Efficacy and safety of as-needed corticosteroid plus fast or short-acting beta-agonists monotherapy in patients with mild asthma: a meta-analysis of randomised controlled trials.
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Year: 2020

Paracetamol increases airway resistance in stable asthmatics: A double blind, randomized, placebo controlled study
Source: Annual Congress 2010 - New or old physiological parameters in chronic airway disorders?
Year: 2010


A single centre, double blind, double dummy, placebo controlled, randomized, three period cross-over phase III trial to demonstrate therapeutic equivalence between a generic and branded inhalation product of ipratropium bromide in subjects with
Source: Eur Respir J 2001; 18: Suppl. 33, 71s
Year: 2001

A multicenter, randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the fluticasone/salmeterol (500/50 μg) combination administered with the new Elpenhaler inhalation device versus the innovative one in patients with asthma
Source: Annual Congress 2009 - Quality of treatment in primary respiratory care
Year: 2009

Airway hyperresponsiveness to mannitol as a predictor of treatment response to ciclesonide in patients with suspected asthma: A double-blind, randomised, placebo-controlled trial
Source: Annual Congress 2012 - Bronchial challenge as a biomarker of respiratory disease
Year: 2012